Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02599194 · ClinicalTrials.gov registry record · Phase 2

18F-FSPG PET/CT for Cancer Patients on Therapy

A Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by Andrei Iagaru.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target
1
Study location

NCT02599194: Completed Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by Andrei Iagaru.

NCT02599194 is a Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative that has completed, run by Andrei Iagaru. The registered enrollment target is 7 participants, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02599194, a Phase 2 study of Stage IIIA Breast Cancer and HER2/Neu Negative, has completed, sponsored by Andrei Iagaru.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Primary Outcome

Standard Uptake Values (SUVs) for the radiotracers labels 18F-FSPG and 18F-FDG were assessed in tumor tissues of study participants, before (baseline), and after therapeutic treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported as the difference of means from ba

Conditions Studied

Stage IIIA Breast Cancer HER2/Neu Negative Estrogen Receptor Negative Progesterone Receptor Negative Stage IIIB Non-small Cell Lung Cancer Stage IIIA Non-Small Cell Lung Cancer Metastatic Renal Cell Cancer Stage III Renal Cell Cancer B-Cell Neoplasm Stage III Mesothelioma

Interventions

  • DRUG 18F-FDG
  • DRUG 18F-FSPG

Study Locations (1)

California

  • Stanford University Medical Center - Stanford

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2015-07
Est. Completion 2016-12-14
Phase Phase 2
Andrei Iagaru

13 total trials

What the finished NCT02599194 record still lists

NCT02599194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 10 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-FDG is the first listed.

NCT02599194 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02599194 about?

NCT02599194 is a clinical study titled "18F-FSPG PET/CT for Cancer Patients on Therapy". The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

What is the current status of trial NCT02599194?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-07. Estimated completion is 2016-12-14.

What conditions does trial NCT02599194 study?

This clinical trial studies the following conditions: Stage IIIA Breast Cancer, HER2/Neu Negative, Estrogen Receptor Negative, Progesterone Receptor Negative, Stage IIIB Non-small Cell Lung Cancer.

What interventions are being tested in trial NCT02599194?

The interventions under investigation include: 18F-FDG (DRUG), 18F-FSPG (DRUG).

Who is sponsoring clinical trial NCT02599194?

This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02599194 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IIIA Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02599194's enrollment target sits among peer trials

7 29th of 29 higher than 1 of 29 other Stage IIIA Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IIIA Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02599194, the US trial registry maintained by the National Library of Medicine. NCT02599194 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.